Lantheus Medical Imaging is highlighting clinical results from a phase III trial for its Pylarify (piflufolastat F-18) radiotracer that will be presented at the virtual 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
A team led by Dr. Steven Rowe of Johns Hopkins University in Baltimore on June 15 will share study results that found that Pylarify "identified and localized metastatic lesions with high positive predictive value regardless of anatomic region in men with biochemically recurrent prostate cancer where standard imaging was uninformative," Lantheus said.
The researchers found the following regarding median positive predictive value (≥ 1 lesion confirmed) by anatomic region:
- 79.5% for the prostate/prostate bed
- 70.9% for pelvic lymph nodes
- 67.4% for the extra-pelvic region
The U.S. Food and Drug Administration cleared Pylarify for the detection of metastatic or recurrent prostate cancer on May 27.
